Literature DB >> 2592158

Association of uveal melanocyte destruction in melanoma-bearing swine with large granular lymphocyte cells.

J T Richerson1, R P Burns, M L Misfeldt.   

Abstract

Sinclair strain miniature swine spontaneously develop and regress malignant melanoma lesions, with uveitis and vitiligo occurring subsequent to tumor regression. Peripheral blood lymphocytes (PBL) of Sinclair swine undergoing tumor regression and melanocyte destruction demonstrated significant lytic activity against K562, porcine semiallogeneic uveal melanocytes, and melanoma cells in 4-h chromium release assays. The ability of porcine PBL to lyse these target cells appears to be an age-associated immune response, as evidenced by the relative inability of PBL of pigs less than 4 weeks old to lyse target cells. In young adult pigs, however, PBL cytotoxic activity significantly increases; piglets 6 weeks old and older demonstrate efficient killing of all three targets. Conjugate formation assays demonstrate that a lymphoid effector cell possessing large granular lymphocyte (LGL) morphology may be involved in melanocyte destruction. These findings suggest that a LGL subpopulation may participate in melanoma and melanocyte destruction which can induce a uveitic syndrome in Sinclair swine with melanoma.

Entities:  

Mesh:

Year:  1989        PMID: 2592158

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  3 in total

1.  Gene expression profiling and regression rate of irradiated uveal melanomas.

Authors:  Rajesh C Rao; Mehnaz Khan; Shahed N Badiyan; J William Harbour
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2015-03       Impact factor: 1.300

2.  Tumor vascularity and hematogenous metastasis in experimental murine intraocular melanoma.

Authors:  H E Grossniklaus
Journal:  Trans Am Ophthalmol Soc       Date:  1998

3.  Incidence of Neoplasia in Pigs and Its Relevance to Clinical Organ Xenotransplantation.

Authors:  Abhijit Jagdale; Hayato Iwase; Edwin C Klein; David Kc Cooper
Journal:  Comp Med       Date:  2019-03-25       Impact factor: 0.982

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.